XTX Topco Ltd bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 10,464 shares of the company's stock, valued at approximately $550,000.
A number of other institutional investors have also recently added to or reduced their stakes in LIVN. Point72 DIFC Ltd boosted its holdings in LivaNova by 75,799.6% in the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company's stock worth $9,531,000 after buying an additional 181,161 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock worth $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new stake in shares of LivaNova during the third quarter worth approximately $1,949,000. Parkman Healthcare Partners LLC raised its stake in LivaNova by 19.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 101,729 shares of the company's stock valued at $5,345,000 after purchasing an additional 16,570 shares during the last quarter. Finally, NFJ Investment Group LLC lifted its holdings in LivaNova by 104.1% in the 3rd quarter. NFJ Investment Group LLC now owns 96,400 shares of the company's stock valued at $5,065,000 after purchasing an additional 49,176 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Insider Transactions at LivaNova
In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.27% of the company's stock.
LivaNova Stock Down 1.2 %
LivaNova stock traded down $0.61 during trading on Friday, reaching $51.50. The stock had a trading volume of 515,221 shares, compared to its average volume of 610,064. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47. The stock has a market cap of $2.80 billion, a PE ratio of 122.62 and a beta of 0.98. The business has a 50 day moving average price of $51.97 and a 200 day moving average price of $51.55.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. Mizuho dropped their target price on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $69.17.
Get Our Latest Stock Report on LivaNova
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
See Also
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
